Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib

Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib

Patients with metastatic colorectal cancer (mCRC) carrying BRAFV600E mutation have worse response to chemotherapy and poor prognosis. The BRAFV600E inhibitor vemurafenib has shown modest efficacy as monotherapy in BRAF-mutated mCRC due to the development of resistance. The aim of this study was to c...

Full description

Bibliographic Details
Main Authors:	Iris Car, Antje Dittmann, Marko Klobučar, Petra Grbčić, Sandra Kraljević Pavelić, Mirela Sedić
Format:	Article
Language:	English
Published:	MDPI AG 2023-04-01
Series:	Biology
Subjects:	BRAFV600E colon cancer secretome BRAF inhibition vemurafenib DNA replication
Online Access:	https://www.mdpi.com/2079-7737/12/4/608

Similar Items

Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro
by: Iris Car, et al.
Published: (2023-08-01)

Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib
by: Petra Grbčić, et al.
Published: (2021-06-01)

The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein
by: Petra Grbčić, et al.
Published: (2021-10-01)

Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
by: Siraj M. Ali, et al.
Published: (2014-05-01)

The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E‐transformed cells
by: Tobias Furlan, et al.
Published: (2018-06-01)

Acquired and intrinsic resistance to vemurafenib in BRAFV600E‐driven melanoma brain metastases
by: Ping Zhang, et al.
Published: (2024-01-01)

Case Report: Vemurafenib Treatment in Brain Metastases of BRAFS365L-Mutant Lung Papillary Cancer by Genetic Sequencing of Cerebrospinal Fluid Circulating Tumor DNA Detection
by: Jianing Jiang, et al.
Published: (2021-06-01)

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
by: Lu Si, et al.
Published: (2018-05-01)

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAFV600E-Mutant CRC: A Case Report and Review
by: Su Min Cho, et al.
Published: (2021-12-01)

IMMUNOHISTOCHEMICAL EXPRESSION OF BRAFV600E IN MELANOMA CASES
by: Muhammad Umer Ch, et al.
Published: (2021-10-01)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
by: Matthias Lang, et al.
Published: (2023-03-01)

Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
by: Raffaella De Paolo, et al.
Published: (2023-07-01)

Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report
by: Ziyao Wang, et al.
Published: (2022-01-01)

BRAFV600E mutation and DSS treatment synergize to induce cecal tumor formation in mice
by: Chenxi Gao, et al.
Published: (2024-03-01)

Glioblastoma with BRAFV600E mutation and numerous metastatic foci: a case report
by: Karolina Janik, et al.
Published: (2019-03-01)

Immunohistochemical Detection of BRAFV600E in Cutaneous Melanocytic Neoplasms in a Cohort of Egyptian Population
by: Nada M. Yakout, et al.
Published: (2022-12-01)

BRAFV600E mutational status assessment in cutaneous melanocytic neoplasms in a group of the Egyptian population
by: Nada M. Yakout, et al.
Published: (2023-02-01)

Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead?
by: Monica Capogiri, et al.
Published: (2023-01-01)

Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells
by: Osrodek M, et al.
Published: (2020-08-01)

Iodine nutritional status is not a direct factor in the prevalence of the BRAFV600E mutation in papillary thyroid cancer
by: Yan-Yu Lin, et al.
Published: (2023-01-01)

Multifocal BRAFV600E-Mutated Melanoma in situ on the Foot
by: Eimei Iwama, et al.
Published: (2015-10-01)

Preoperative detection of TERT promoter and BRAFV600E mutations in papillary thyroid carcinoma in high-risk thyroid nodules
by: Tatiana Marina Vieira Giorgenon, et al.
Published: (2019-03-01)

An effective treatment in Erdheim Chester disease: vemurafenib: a case report
by: Ersin Bozan, et al.
Published: (2023-10-01)

Metastatic pattern is a prognostic factor in BRAFV600E mutant colorectal cancer
by: Jingran Ji, et al.
Published: (2023-01-01)

PD-L1 Is an Independent Prognostic Marker in Middle Eastern PTC and Its Expression Is Upregulated by <i>BRAFV600E</i> Mutation
by: Abdul K. Siraj, et al.
Published: (2021-02-01)

Relationship of the recurrence after pterygium surgery with the presence of HSV, EBV, CMV, HPV, and BRAFV600E mutation
by: S.O. Rykov, et al.
Published: (2019-02-01)

Vemurafenib Treatment of Pleomorphic Xanthoastrocytoma in a Child With Down Syndrome
by: Giuseppe Petruzzellis, et al.
Published: (2019-04-01)

AI‐BRAFV600E: A deep convolutional neural network for BRAFV600E mutation status prediction of thyroid nodules using ultrasound images
by: Chuang Xi, et al.
Published: (2023-04-01)

Sarcoidosis is not associated with BRAFV600E mutation
by: Christian D. Becker, et al.
Published: (2017-01-01)

Vemurafenib for BRAF V600‐mutant Erdheim–Chester disease presenting with bilateral orbital involvement
by: Xiaomeng Wang, et al.
Published: (2023-08-01)

Computer-aided design and synthesis of 3-carbonyl-5-phenyl-1H-pyrazole as highly selective and potent BRAFV600E and CRAF inhibitor
by: Jinwoong Kim, et al.
Published: (2019-01-01)

Age and BRAFV600E Mutation Stratified Patients with Cytologically Benign Thyroid Nodules
by: Huang G, et al.
Published: (2023-12-01)

Delayed-onset vemurafenib-induced panniculitis
by: Stephen L. Vance, MD, MBA, et al.
Published: (2017-09-01)

Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma
by: Hilal Eser Öztürk, et al.
Published: (2020-01-01)

Melanoma-Derived BRAFV600E Mutation in Peritumoral Stromal Cells: Implications for in Vivo Cell Fusion
by: Zsuzsanna Kurgyis, et al.
Published: (2016-06-01)

Meta-Analyses of Association Between BRAFV600E Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma
by: Qing Zhang, et al.
Published: (2016-02-01)

Sox10-Deficient Drug-Resistant Melanoma Cells Are Refractory to Oncolytic RNA Viruses
by: John Abou-Hamad, et al.
Published: (2023-12-01)

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
by: Castellani Elisa, et al.
Published: (2012-07-01)

BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters
by: Faruk Erdem KOMBAK, et al.
Published: (2019-05-01)

Indolent renal involvement with BRAFV600E mutation: Erdheim‐Chester, a rare disease with a wide spectrum of clinical manifestations
by: Charlotte Vanhomwegen, et al.
Published: (2021-08-01)